Oncology Clinical Pathways: Charting the Landscape of Pathway Providers.
Publication
, Journal Article
Daly, B; Zon, RT; Page, RD; Edge, SB; Lyman, GH; Green, SR; Wollins, DS; Bosserman, LD
Published in: J Oncol Pract
March 2018
Duke Scholars
Published In
J Oncol Pract
DOI
EISSN
1935-469X
Publication Date
March 2018
Volume
14
Issue
3
Start / End Page
e194 / e200
Location
United States
Related Subject Headings
- Quality of Health Care
- Quality Improvement
- Oncology & Carcinogenesis
- Medical Oncology
- Humans
- Decision Support Techniques
- Critical Pathways
- Cost-Benefit Analysis
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Daly, B., Zon, R. T., Page, R. D., Edge, S. B., Lyman, G. H., Green, S. R., … Bosserman, L. D. (2018). Oncology Clinical Pathways: Charting the Landscape of Pathway Providers. J Oncol Pract, 14(3), e194–e200. https://doi.org/10.1200/JOP.17.00033
Daly, Bobby, Robin T. Zon, Ray D. Page, Stephen B. Edge, Gary H. Lyman, Sybil R. Green, Dana S. Wollins, and Linda D. Bosserman. “Oncology Clinical Pathways: Charting the Landscape of Pathway Providers.” J Oncol Pract 14, no. 3 (March 2018): e194–200. https://doi.org/10.1200/JOP.17.00033.
Daly B, Zon RT, Page RD, Edge SB, Lyman GH, Green SR, et al. Oncology Clinical Pathways: Charting the Landscape of Pathway Providers. J Oncol Pract. 2018 Mar;14(3):e194–200.
Daly, Bobby, et al. “Oncology Clinical Pathways: Charting the Landscape of Pathway Providers.” J Oncol Pract, vol. 14, no. 3, Mar. 2018, pp. e194–200. Pubmed, doi:10.1200/JOP.17.00033.
Daly B, Zon RT, Page RD, Edge SB, Lyman GH, Green SR, Wollins DS, Bosserman LD. Oncology Clinical Pathways: Charting the Landscape of Pathway Providers. J Oncol Pract. 2018 Mar;14(3):e194–e200.
Published In
J Oncol Pract
DOI
EISSN
1935-469X
Publication Date
March 2018
Volume
14
Issue
3
Start / End Page
e194 / e200
Location
United States
Related Subject Headings
- Quality of Health Care
- Quality Improvement
- Oncology & Carcinogenesis
- Medical Oncology
- Humans
- Decision Support Techniques
- Critical Pathways
- Cost-Benefit Analysis
- 1112 Oncology and Carcinogenesis